Diabetes Health Professional
Take the Diabetes Health Pump Survey
Diabetes Health magazine
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • Eating Well (or at Least Not terribly) at Fast Food Resturants
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
next
Latest
Popular
Top Rated

Latest Professional Issues Articles

Doctors Can Be Everyday Heroes, Too
Lantus and Levemir: What's the Difference?
A Prodigious Future for Prodigy Diabetes Care
Diabetes Educator Mentorship Program
Some Doctors Dispute Benefits Of Early Diagnosis
New Primary Care Physicians Haven't Learned Enough About Diabetes
UCSF Opens High-tech Learning Center for New Era of Health Care
Drug Shortage Worries the Medical Community, Calls for Emergency Action
Could the iPad Save Your Life?
Patient/Provider Language Barriers Linked to Worse Diabetes Control
Diabetes Health Reference Charts
Type 2 Meds Reference Guide (PDF)
Insulin Pumps Reference Guide (PDF)
Insulin Pen Needles Reference Guide (PDF)
Insulin Pens Reference Guide (PDF)
Insulin Pens Reference Guide (PDF)
Syringes Reference Guide (PDF)
Insulin Pens Reference Guide (PDF)
Insulin Pens Reference Guide (PDF)
Mail Order Reference Guide (PDF)
Fast Acting Glucose Reference Guide (PDF)
See All Charts…
Professional Issues Archives
Browse the Professional Issues Archives
Subscribe to the Community RSS Feed
Print | Email | Share | Comments (0)

PKC Inhibitor Maintains the Kidney Health of Your Type 2 Patients

From the Spring Research Guide


Apr 1, 2006

Sacred Heart Medical Center, Spokane, WA

For type 2s who suffer from kidney disease, treatment with ruboxistaurin was shown to reduce albuminuria and maintain estimated glomerular filtration rate (eGFR) for more than one year. Ruboxistaurin—a PKC inhibitor manufactured by Eli Lilly and Company—may have added benefit in established therapies for diabetic kidney disease.

Researchers at the Heart Institute and Sacred Heart Medical Center in Spokane, Washington, conducted a randomized double-blind placebo-controlled multicenter study to evaluate the effects of 32 mg per day of ruboxistaurin for one year in 123 people with type 2 diabetes and persistent albuminuria despite therapy with renin-angiotensin system inhibitors.

After one year, urinary albumin-to-creatinine ratio (ACR) decreased 24 percent in participants treated with ruboxistaurin compared to 9 percent in the placebo group. Participants’ eGFR did not decline significantly in the ruboxistaurin group, whereas the placebo group lost significant eGFR over one year.

—Diabetes Care, November 2005

Categories: Diabetes, Diabetes, Kidney Care (Nephropathy), Professional Issues, Type 2 Issues

Donate to Diabetes Health

You May Also Be Interested In...

Click Here To View Or Post Comments

Comments 0 comments - Apr 1, 2006

©1991-2013 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.